Hormone receptor-positive breast cancer

This early-phase study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard therapies. The main goals are to check the drug's safety and find the right dose, while also seeing if …

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This study tests whether the drug elacestrant can clear traces of cancer DNA found in the blood of people with hormone receptor-positive breast cancer who are at risk of late recurrence. About 50 adults whose blood tests positive for tumor DNA but show no visible spread will take…

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormon…

Researchers are testing whether dalpiciclib, a targeted cancer drug, combined with toremifene, a hormonal therapy, can slow the growth of advanced HR-positive, HER2-negative breast cancer when used as a first-line treatment. The trial plans to enroll 36 women who have not yet rec…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This trial tests whether adding an experimental drug called culmerciclib to standard hormone therapy can shrink tumors more effectively in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Participants receive either the combination or hormone therap…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This study tests a new drug called BGB-43395 combined with letrozole against standard CDK4/6 inhibitor drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole for people with advanced or metastatic HR+/HER2- breast cancer who have not had prior treatment for advanced disea…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

Inavolisib treats certain PIK3CA-mutated, HR-positive, HER2-negative breast cancers but can raise blood sugar. Researchers at Tianjin Medical University Cancer Institute and Hospital are studying whether matching blood sugar monitoring and preventive metformin to each patient's r…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This study tests whether a new quarterly injection of letrozole delivers the same amount of medicine into the body as the standard daily pill. It involves 120 postmenopausal women who have already completed at least 4-5 years of hormone therapy for early breast cancer. The goal i…

This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants w…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

Researchers are testing whether adding the blood pressure drug olmesartan to dalpiciclib and standard hormone therapy helps women with HR+/HER2- advanced breast cancer. The trial enrolls 40 women aged 18 to 75 with locally advanced or metastatic disease. Everyone receives the thr…

This Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …

This study tests a new drug called GDC-4198, alone or combined with another drug (giredestrant), against a standard treatment (abemaciclib plus giredestrant) in people with advanced ER+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. The trial has two …

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new oral drug called imlunestrant in premenopausal women with estrogen receptor-positive, HER2-negative breast cancer. Some participants will also receive a drug to suppress ovarian function. The effects on tumor cells and ovaries will be compared with those of…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This early-phase study tests a new drug called IEV407, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 194 participants will take p…

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This phase 2 trial is testing whether adding a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) to elacestrant works better than elacestrant alone for people with advanced ER+/HER2- breast cancer that has already been treated with a CDK4/6 inhibitor. The study will enro…

This study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated yet in the advanced setting will …

This trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many …

This study tests whether adding tocilizumab, an anti-inflammatory drug, to standard chemotherapy improves outcomes for people with metastatic triple-negative or ER-low breast cancer. Researchers will compare the combination to chemotherapy alone in 168 Black and non-Black patient…

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This study tests a new combination of two drugs (saruparib and camizestrant) against standard treatments for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people with inherited BRCA1, BRCA2, or PALB2 mutations. The goal is to see if the new…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study is testing whether a simple blood test that looks for cancer DNA can help doctors decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will have their blood tested every 3 months for…

This Phase 3 study tests whether a new drug, inavolisib, combined with fulvestrant works better than the current standard alpelisib plus fulvestrant for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The trial enrolled …

This study tests whether combining the drug inavolisib with other treatments can safely shrink or eliminate early-stage breast tumors that have a specific genetic change (PIK3CA mutation). About 60 people with untreated stage II-III breast cancer will receive the drug combination…

This study tests MK-5684, a drug that blocks the body from making steroid hormones, in people with breast, ovarian, or endometrial cancer. Researchers want to see if it helps patients live longer without their cancer growing compared to standard treatments. The trial is recruitin…

This study is testing a drug called Dato-DXd in 100 people with a type of advanced breast cancer (HR-positive, HER2 IHC 0) that has stopped responding to hormone therapy. Participants receive the drug by IV every 3 weeks. The goal is to see if it can slow cancer growth and to che…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 particip…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This study tests a new drug called ECI830, alone or with other cancer drugs (ribociclib and fulvestrant), in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination can slow can…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This study tests a device called TheraBionic P1 that sends low-level electromagnetic fields to the body. It is for people with advanced hormone-positive, HER2-negative breast cancer who have already tried standard treatments. The goal is to see if the device can help control the …

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study tests different hormone therapies in men with breast cancer before they have surgery. The goal is to see which treatment works best to shrink the tumor. About 60 men with hormone receptor-positive breast cancer will take part.

This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy (albumin paclitaxel and epirubicin) before surgery can improve outcomes for people with early-stage HR+/HER2- breast cancer. The study focuses on how well the combination shrinks tumo…

This phase 2 trial tests whether the chemotherapy pill capecitabine can eliminate tiny amounts of cancer DNA still present in the blood after standard treatment for early-stage ER+/HER2- breast cancer. About 15 patients whose blood tests show residual cancer DNA will take capecit…

This study looks at how well sacituzumab tirumotecan (SKB264) works, either alone or with other treatments, in people with advanced HER2-negative breast cancer that has spread or come back. It includes two groups: those with triple-negative breast cancer and those with hormone re…

This phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …

This study tests whether a blood test that looks for cancer DNA (ctDNA) can find breast cancer returning earlier than usual scans or exams. About 976 people with HR-positive/HER2-negative early breast cancer who had surgery will give blood samples over time. If the test shows sig…

This phase 2 trial is testing whether giving a short course of targeted radiation (SBRT) followed by a reduced-dose chemotherapy (nab-paclitaxel) plus an immunotherapy drug (toripalimab) before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer.…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participan…

This early-stage trial tests a new oral drug called RGT-419B, given alone or with hormone therapy, in 64 adults with a specific type of advanced breast cancer (HR+/HER2-) that has worsened after prior treatment. The main goal is to check safety and find the right dose, while also…

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This phase 2 trial tests whether a probiotic blend called WBF-038 can prevent bone loss in women with early-stage hormone receptor-positive breast cancer who are about to start aromatase inhibitor therapy. Aromatase inhibitors lower estrogen, which can weaken bones. The study wil…

This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dos…

This phase 2 trial is testing whether a less extensive lymph node surgery, called targeted axillary dissection (TAD), can safely control cancer in women aged 45 and older with early-stage ER+ breast cancer that has spread to lymph nodes detected by ultrasound. Participants will h…

This study looks at how well ribociclib, a targeted cancer drug, works when added to hormone therapy for people with HR+ HER2- stage II or III breast cancer. It will follow about 2,766 patients in Russia, comparing those who get ribociclib plus hormone therapy to those who got ho…

This Phase 3 trial tests whether the drug elacestrant can help prevent breast cancer from coming back in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant or standard hormone therapy for up to 7.5 years. The study compar…

This phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…

This early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will t…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study looks at whether a genetic test (Prosigna®) can help decide if younger women with early, hormone-sensitive breast cancer need chemotherapy. About 3380 premenopausal women will either get standard treatment (chemo plus hormone therapy) or a treatment plan based on the t…

This study follows about 3,250 people with HR+/HER2- early breast cancer who are at high risk of recurrence. Participants take ribociclib (Kisqali) plus an aromatase inhibitor as part of their routine care. Researchers will track how well the treatment works in real life, its sid…

This study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progre…

This study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a certain type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a specific ge…

This early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …

This study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The cancer has continued to grow despite at least two prior hormone treatments. The goal is to find the best dose of alisertib and see if t…

This phase 3 trial compares an experimental drug called BL-B01D1 to standard chemotherapy in people with a common type of breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and cannot be removed by surgery. The study aims to see if BL-B01D1 can delay cancer …

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This study tracks 108 patients with HR-positive, HER2-negative advanced breast cancer who are receiving abemaciclib combined with hormone therapy. Researchers are collecting real-world data on how long patients live without their cancer worsening, overall survival, and side effec…

This phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells,…

This study tests whether postmenopausal women with a very low-risk type of breast cancer (HR+ HER2-) can safely take hormone therapy for only 2-3 years instead of the standard 5 years. The goal is to maintain protection against cancer spread while reducing side effects and improv…

This trial investigates whether adding simvastatin, a widely used cholesterol medication, to the standard hormone therapy letrozole can better slow the growth of hormone receptor-positive, HER2-negative breast cancer before surgery. About 40 adults with stage I-III breast cancer …

This trial investigates whether women aged 60 and older with a very small, low-risk type of breast cancer can safely avoid hormone therapy after surgery. Participants will not receive standard drugs like tamoxifen or letrozole, and researchers will track cancer recurrence for up …

This clinical trial is testing a combination of three drugs—entinostat, pyrotinib, and endocrine therapy—in people with advanced triple-positive breast cancer (cancer that is both hormone receptor-positive and HER2-positive) whose disease has worsened after prior treatment with t…

This study tests whether personalized coaching based on patient typology helps women with HR+/HER2- early breast cancer stick with their ribociclib treatment longer. About 548 participants will either receive standard education or tailored coaching using a validated tool. The goa…

This study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning ag…

This study tests whether a bilingual smartphone app, combined with patient navigation, can help Latina breast cancer patients take their hormone therapy as prescribed. Many patients struggle with barriers like cost, insurance, or language that make it hard to stay on treatment. T…

This early-phase study is testing whether the drug ribociclib (Kisqali) can be safely given alongside standard radiation therapy after surgery for women with a high-risk type of breast cancer (HR+/HER2-). About 30 participants will take ribociclib daily for up to 6 weeks while re…

This study tests a new combination of drugs (L-Ornithine L-Aspartate, N-Acetylcysteine, CDK4/6 inhibitors, and Fulvestrant) in 40 women with HR-positive/HER2-negative advanced breast cancer whose disease got worse after standard therapy. The goal is to see if the combo can shrink…

This phase 2 trial tests a personalized approach for early-stage, hormone receptor-positive breast cancer. Participants receive a combination of CDK4/6 inhibitors and endocrine therapy before surgery. A blood test (ctDNA) is used to monitor tumor DNA and may help decide if chemot…

This study tests whether a blood test (ctDNA) can identify women with early-stage, hormone-positive breast cancer who can safely avoid chemotherapy. Instead of chemo, they receive a targeted pill (dalpiciclib) plus hormone therapy before surgery. The goal is to reduce side effect…

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

This phase II trial is testing whether giving the hormone therapy drug goserelin (Zoladex) as a shot in the upper buttock works as well as the standard belly injection for suppressing ovarian function in premenopausal women with hormone-positive breast cancer. About 98 patients w…

This phase 3 trial is testing whether premenopausal women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy if their tumor responds well to hormone therapy before surgery. About 950 women will be randomly assigned to either standard surgery first or hor…

This study tests whether slowly increasing the dose of the drug abemaciclib over three weeks helps patients with early-stage HR+HER2- breast cancer stay on the full approved dose. About 50 participants will receive the drug alongside hormone therapy. The main goal is to see if mo…

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study follows 177 people with HR+/HER2- early breast cancer who are already taking ribociclib with hormone therapy as part of their routine care. Researchers will track how well the treatment works and any side effects over time. The goal is to see if the drug helps prevent …

This study tests two experimental drugs, sapanisertib and serabelisib, combined with standard therapy for people with HR+/HER2- advanced or metastatic breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the disease. About 32 adults w…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This phase 2 trial tests whether a new drug called culmerciclib, combined with fulvestrant, works better than standard CDK4/6 inhibitors plus fulvestrant for people with HR-positive, HER2-negative breast cancer that has worsened after first-line hormone therapy. About 98 women ag…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-) that has returned or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adults a…

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This study tracks the safety and effectiveness of Piqray (Alpelisib) in people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation). It includes postmenopausal women and men whose cancer worsened after hormone therapy. Researchers observe patients i…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This phase 2 trial is testing a combination of two drugs—deruxtecan (a targeted chemotherapy) and ivonescimab (an immunotherapy)—in people with hormone receptor-positive, HER2-negative advanced breast cancer. The study aims to see how well the combination shrinks tumors and how s…

This study is for women with early-stage luminal breast cancer that has spread to 1 or 2 lymph nodes. Instead of removing many lymph nodes from the armpit, surgeons will remove only the marked suspicious node and the sentinel nodes. If fewer than 3 nodes are positive, full lymph …

This expanded access program provides giredestrant, a daily oral drug, to people with ER-positive, HER2-negative breast cancer (early or advanced) who have limited treatment options. The goal is to offer early access before the drug is commercially available in the US. Participan…

This study tests whether the drug everolimus can help women with a common type of advanced breast cancer (HR-positive, metastatic) whose cancer has stopped responding to a similar drug called alpelisib. The trial will enroll 19 women and measure how many see their tumors shrink. …

This phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…

This study tests a combination of two drugs—elacestrant and trastuzumab deruxtecan—in people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultralow) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The goal is to find the s…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This phase II study tests a personalized approach for women with a common type of early breast cancer (HR+/HER2-). All 45 participants start with a combination of culmerciclib and hormone therapy. If the tumor responds well, they continue; if not, they switch to a different treat…

This study tests a new drug called fovinaciclib combined with hormone therapy and targeted antibodies in people with early-stage HR-positive/HER2-positive breast cancer. After 6 weeks, doctors check if the tumor is shrinking. If it is, patients continue the same treatment; if not…

This study tests two drugs, camizestrant and ribociclib, together in people with advanced hormone receptor-positive (HR+) breast cancer. The goal is to see if the combination can delay cancer growth better than current treatments. About 150 adults who have already received hormon…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-stage trial tests the drug abemaciclib (a CDK4/6 inhibitor) given together with targeted radiation for people with metastatic HR+ HER2- breast cancer that has spread to bone. The main goal is to find the safest dose of abemaciclib when combined with radiation. About 28…

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This phase 3 study tests whether the experimental drug YL202 works better than standard treatments (like eribulin or capecitabine) for people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least one chemotherapy. About 376 participants will …

This study tests a new drug called GenSci145 in people whose advanced solid tumors have a specific change in the PIK3CA gene. The trial has two parts: first, finding a safe dose, then seeing if the drug works alone or with other treatments. About 186 adults aged 18-75 with tumors…

This study is for people with a common type of breast cancer (ER-positive, HER2-negative) that has a moderate to high risk of coming back based on tumor size and lymph node involvement, but a low genetic risk score. Instead of chemotherapy after surgery, participants can choose t…

This Phase 3 study tests whether adding the experimental drug gedatolisib to standard hormone therapy and palbociclib can delay cancer growth better than the current standard treatment (hormone therapy plus ribociclib) in people with HR-positive, HER2-negative advanced breast can…

This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer. About 55 participants will receive the combination, and researchers will measure how man…

This phase 2 trial is testing whether combining two hormone-blocking drugs, elacestrant and exemestane, can help people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to initial treatments. The study uses a special PET scan to select partici…

This study is testing whether adding the drug dalpiciclib to standard hormone therapy can help prevent breast cancer from coming back in women with early-stage HR+/HER2- breast cancer. About 2,000 women will receive either a higher dose for 2 years or a lower dose for 3 years, al…

This phase 2 trial is testing a new drug, trastuzumab rezetecan, against an existing drug, trastuzumab deruxtecan, in 150 women with a common type of advanced breast cancer (HR-positive, HER2-low). The goal is to see which dose works best to slow cancer growth. Participants must …

This study tests a combination of two drugs (Sac-TMT and Tagitanlimab) in 35 people with a specific type of advanced breast cancer that is hormone receptor-positive, HER2-negative, and PD-L1-positive. Participants must have already been treated with a CDK4/6 inhibitor. The goal i…

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy for people with a common type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy. About 430 participants will be randomly assigned to receive either SKB264 or one of …

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy in 376 people with advanced HR+/HER2- breast cancer that has worsened after at least one chemotherapy. The goal is to see if SKB264 can slow cancer growth or improve survival. Participants are randoml…

This phase 2 trial is testing the safety of abemaciclib (Verzenio) combined with hormone therapy in people aged 70 and older with hormone receptor-positive metastatic breast cancer that has worsened after prior treatment with a similar drug. The study will enroll 43 participants …

This study looks at whether using a mobile app helps people with HR+ HER2- stage II or III breast cancer stick to their prescribed ribociclib and aromatase inhibitor therapy for a full year. The app provides reminders and information about side effects and relapse risks. About 24…

This Phase 3 trial is testing whether a new drug called PF-07248144, taken with fulvestrant, can help people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatment. About 400 participants will either receive the new co…

This Phase 2 trial tests a new oral drug called SPH4336 combined with standard hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study aims to see if the combination can shrink brain tumors and control the disease. About 52…

This study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combinat…

This study is for people with a type of advanced breast cancer called HR+/HER2-negative. It tests a new drug, VS-6766, combined with two standard drugs (abemaciclib and fulvestrant). The goal is to find the safest dose and see if the combination can shrink tumors or stop them fro…

This phase II trial tests whether taking leucogen alongside standard ribociclib therapy can prevent severe neutropenia (dangerously low white blood cell counts) in women with early-stage hormone-positive breast cancer. About 94 participants will receive the combination and be mon…

This phase III trial tests whether adding ribociclib to standard hormone therapy (aromatase inhibitor) can prevent breast cancer from coming back in women with hormone receptor-positive, HER2-negative early breast cancer who still have cancer after initial chemotherapy. About 446…

This phase 2 trial is testing whether the drug elacestrant, given alone or with triptorelin (which temporarily stops ovary hormone production), can slow or shrink hormone-sensitive breast tumors in premenopausal women. About 96 women will take the pills daily for 30 days before t…

This early-stage trial tests a new drug called TOS-358 in women with advanced HR+ HER2- breast cancer that has a specific mutation in the PIK3CA gene. The study aims to find the safest dose and see if the drug works alone or with standard treatments like fulvestrant and CDK4/6 in…

This pilot study is testing whether a device called TheraBionic P1, which delivers targeted electromagnetic fields, can affect breast cancer tumors before surgery. About 24 women with early-stage, hormone receptor-positive, HER2-negative breast cancer will use the device three ti…

This study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the triple combination is safe and can reduce high blood sugar side effects often caused by the standard drugs. About 52 adul…

This study tests a new drug, zunsemetinib, combined with standard chemotherapy (capecitabine) in people with a common type of advanced breast cancer (HR+/HER2-) that has spread to the bones. The goal is to see if the combination is safe and can slow down the cancer or reduce bone…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This program provides access to the drug alpelisib (BYL719) for patients with PIK3CA-related overgrowth spectrum or breast cancer who have no other treatment options and cannot join a clinical trial. It is not a study but a way for doctors to request the drug for individual patie…

This study tests a combination of two drugs, ribociclib and anastrozole, in people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has spread or come back. The goal is to see if the combo can shrink tumors and how safe it is. About 86 adults in Japa…

This study tests two drugs, abemaciclib and bicalutamide, together in people with a type of metastatic breast cancer that has spread and is positive for androgen receptors but negative for HER2. The goal is to find the safest dose and see if the combination can control the diseas…

This phase II trial is testing whether using specific genetic tests (Ki67 and Oncotype DX) can help doctors choose the best treatment before surgery for women with a common type of breast cancer (ER-positive, HER2-negative). The study includes 81 postmenopausal women with stage I…

This study tests whether an artificial intelligence model can identify patients with advanced HR+ HER2- breast cancer whose tumors might still respond to a second CDK4/6 inhibitor after the first stopped working. About 105 participants will either receive the AI-recommended drug …

This study tests a vaccine called STEMVAC in people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to help the immune system attack cancer cells. Participants will receive STEMVAC along with their usual hormone therapy, a targ…

This early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…

This Phase 2 trial tests whether adding entinostat to a two-drug regimen (dalpiciclib and letrozole) before surgery can better shrink tumors in women with HR-positive, HER2-negative early breast cancer. Sixty participants will receive either the three-drug combo or the standard t…

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This phase 3 trial compares a new oral drug, D-0502, against the standard injection fulvestrant for people with ER-positive, HER2-negative advanced or metastatic breast cancer. The study aims to see if D-0502 can delay cancer growth better than fulvestrant. About 640 participants…

This study tests whether adding tinengotinib to fulvestrant can shrink tumors in people with a common type of advanced breast cancer (HR+/HER2-). About 94 adults whose cancer has returned or spread despite prior treatments will take part. The goal is to find the best dose and see…

This Phase 3 trial tests whether adding a chemotherapy drug (capecitabine) to a standard two-drug regimen (dalpiciclib plus hormone therapy) can slow cancer growth longer in people with HR+/HER2- breast cancer that has spread to internal organs. About 258 participants will be ran…

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or retur…

This study is for people with certain types of breast cancer (HER2-positive or triple-negative) who have a complete response to initial drug therapy. It tests whether they can safely skip surgery and only receive radiation, or skip radiation if surgery shows no cancer left. For a…

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…

This study tests whether tirzepatide, a weight-loss medication, combined with standard hormone therapy can help clear tiny amounts of cancer DNA from the blood of people with obesity or overweight who have had hormone-positive, HER2-negative, node-positive early breast cancer. Th…

This study tests a new drug called FWD1802 in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part. The study has…

This early-phase study tests an experimental vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). The vaccine is injected directly into the tumor alongside standard chemotherapy before surgery. The goal is to find the saf…

This Phase 2 trial is testing whether combining trastuzumab rezetecan (a targeted drug) with toripalimab (an immunotherapy) before surgery can eliminate more tumor tissue in women with HR-positive, HER2-low breast cancer. About 111 participants will receive the drug combo for 24 …

This study is testing a drug called dalpiciclib in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the drug can keep the cancer from growing and what side effects it causes. About 103 participants will take dalpicicl…

This study tests a combination of two drugs, fulvestrant and abemaciclib, for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a first-line treatment called a CDK4/6 inhibitor. The goal is to see if taking a break fr…

This phase 2 trial is testing a new approach for post-menopausal women with HR+HER2- breast cancer. Participants receive standard hormone therapy plus focal radiation, and some also get the immunotherapy drug pembrolizumab and an immune booster (CDX-301). The goal is to see if th…

This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …

This phase 2 study is testing several drug combinations (fulvestrant plus either neratinib, alpelisib, or everolimus) in 135 postmenopausal women with advanced ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitor treatment. The goal is to see which combination offer…

This study tests whether tirzepatide, a drug used for weight loss, can help patients with early-stage hormone receptor-positive, HER2-negative breast cancer lose at least 5% of their body weight during adjuvant treatment. The trial will enroll 40 adults and also check safety, sid…

This phase 2 trial is testing whether using gene tests (MammoPrint and BluePrint) to guide treatment can help people with a certain type of advanced breast cancer (HR+, HER2-negative) live longer. 64 participants will receive either chemotherapy (capecitabine) or hormone therapy …

This study tests a new oral drug called SPH4336 combined with hormone therapy (letrozole or fulvestrant) in people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after prior treatment. About 254 participants will receive either the dru…

This early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progresse…

This study tests whether adding two drugs (entinostat and anlotinib) to a standard hormone therapy (fulvestrant) can shrink tumors or slow cancer growth in people with a common type of advanced breast cancer (HR+/HER2-). About 118 adults whose cancer returned or worsened after pr…

This study tests two drugs together (HRS-8080 and dalpiciclib) in people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combination can shrink tumors. About 146 women aged 18-75 will take part…

This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate more cancer in people with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then have surgery. After surgery…

This study is testing whether giving chemotherapy on a faster schedule (called dose-dense) works better for women with a common type of breast cancer (HR+/HER2-) that grows quickly (high Ki67). About 64 women will receive the faster chemo before surgery to see if it reduces the a…

This phase 2 trial tests a new treatment plan for people with a certain type of advanced breast cancer (HR-positive, HER2-low or ultra-low). Participants first receive trastuzumab rezetecan alone for several months, then switch to a combination of CDK4/6 inhibitors and hormone th…

This phase 3 trial is testing whether adding a new oral drug called JS105 to two standard drugs (dalpiciclib and fulvestrant) can better control advanced breast cancer in people with a PIK3CA gene mutation. The study will enroll 312 adults with HR-positive, HER2-negative breast c…

This Phase 2 trial tests whether adding targeted radiation (SBRT) to standard hormone therapy and a CDK4/6 inhibitor can help women with metastatic HR+ HER2- breast cancer live longer without their disease worsening. About 102 participants will be randomly assigned to receive eit…

This study tests whether a blood test measuring thymidine kinase activity (TKa) can help doctors decide early if a patient's breast cancer treatment is working. Patients with HR+ HER2- metastatic breast cancer start standard therapy with a CDK4/6 inhibitor and endocrine therapy. …

This study tests two different doses of the drug dalpiciclib combined with letrozole in 120 women with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the cancer stays under control and how safe the treatment is. Participants wi…

This pilot study tests a new way of giving several already-approved chemotherapy drugs in a specific order to treat hormone-positive metastatic breast cancer. The idea is to hit the cancer with a 'first strike' and then a 'second strike' to make treatment more effective. The stud…

This study tests whether adding elacestrant to the standard drug olaparib can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a BRCA gene mutation. About 176 participants will be randomly assigned to receive either the combination o…

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This study tests a new drug called QL1706 in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if it can slow down the cancer's growth and check for side effects. About 123 women will take part, and the results will be compared to standard care.

This study is looking at whether taking a CDK4/6 inhibitor (either abemaciclib or ribociclib) after surgery can help prevent breast cancer from coming back in people with HR+/HER2- breast cancer. The researchers will follow 229 participants to see how long they stay cancer-free a…

This early-phase study is testing whether giving radiation therapy together with two drugs (abemaciclib and letrozole) before surgery is safe and doable for people with a common type of early-stage breast cancer (HR+/HER2-). About 15 participants will receive this combination to …

This phase II trial is testing whether a targeted drug called trastuzumab deruxtecan (Enhertu), given alone or with anastrozole (Arimidex), can eliminate HER2-low, hormone receptor positive breast cancer before surgery. The study will enroll 88 people with early-stage breast canc…

This early-stage trial tests whether adding avasopasem to standard hormone therapy and a CDK4/6 inhibitor can help women with metastatic hormone receptor-positive breast cancer that has stopped responding to treatment. The study will enroll 35 participants and focus on safety, wh…

This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test i…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapy can prevent breast cancer from coming back or spreading in people whose cancer has returned in the same breast, chest wall, or nearby lymph nodes. About 290 participants will receive either h…

This study tests a new drug combination (invikafusp alfa plus sacituzumab govitecan) in people with advanced breast cancers that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and can shrink or control tumors. About 50 adults with tripl…

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This study is testing a new oral drug called dalpiciclib in 420 people with hormone receptor-positive advanced breast cancer. Researchers are watching how well it works and what side effects occur in everyday medical practice, not a strict lab setting. The goal is to see if it ca…

This program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria …

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study tests whether an artificial intelligence model can predict which patients with HR+/HER2- breast cancer will benefit most from chemotherapy given before surgery. Researchers will use pre-treatment MRI scans to classify patients into high- or low-benefit groups and compa…

This study enrolls 100 people with metastatic, hormone receptor-positive, HER2-negative breast cancer to compare different genetic testing methods for detecting PIK3CA mutations. Researchers will check how well newer DNA sequencing techniques match up with standard PCR tests. The…

This study aims to create a blood test (liquid biopsy) that can detect two key genetic mutations, ESR1 and gBRCA, in patients with a common type of metastatic breast cancer (HR+/HER2-). The test would help doctors choose the most effective treatments without needing a tissue biop…

This trial tests whether pharmacopuncture, a treatment that injects small amounts of herbal medicine into acupuncture points, can reduce joint pain in women with breast cancer who take aromatase inhibitors. These drugs often cause joint pain, and the study compares pharmacopunctu…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…

This study tests whether prolonged overnight fasting, exercise, or both can reduce fatigue in women with advanced breast cancer who are taking CDK4/6 inhibitors with endocrine therapy. Participants will follow a 12-week program of fasting for 12-14 hours overnight, an exercise ro…

This pilot trial tests whether a 12-week virtual tai chi program can reduce joint pain in postmenopausal women with hormone receptor-positive breast cancer who are taking aromatase inhibitors. Participants are randomly assigned to tai chi classes or health education sessions. The…

This trial tests whether a 12-week slow jogging program can help breast cancer survivors sleep better, feel less tired, and enjoy a better quality of life. Women who have finished primary treatment for hormone receptor-positive breast cancer will either jog slowly three times a w…

This trial tests whether a six-month intermittent fasting plan—fasting for about 14 hours each night and eating within a 10-hour daytime window—is something women with early-stage, hormone-positive breast cancer can stick to while on hormone therapy. The goal is to see if this ea…

This phase II trial tests whether giving preventive medications (loperamide for diarrhea and cetirizine for rash) can reduce common side effects of the cancer drug capivasertib when combined with fulvestrant. About 108 adults with HR+/HER2- metastatic breast cancer will participa…

This study tests a mobile health tool to help women on hormone therapy for breast cancer track and manage side effects. About 60 women who recently started hormone therapy will use the app to report symptoms and get health tips. The goal is to see if the app is easy to use and he…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in women who have had breast cancer and are taking hormone therapy. About 92 women will be randomly assigned to receive either fezolinetant or a placebo daily for 12 weeks. The main goal is to measure…

This study tracks how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. Researchers will measure changes in quality of life and symptoms using patient questionnaires. The goal is to see which treatmen…

This study is testing whether a 12-week physical activity program can improve quality of life and reduce pain in women with early-stage hormone receptor positive breast cancer who are on hormone therapy. About 44 participants will join an exercise program and fill out questionnai…

This study tests whether Revaree Plus, a hyaluronic acid vaginal suppository, can improve vaginal dryness in women with hormone-receptor-positive breast cancer. About 60 participants will use the suppository for 8 weeks. Researchers will measure changes in vaginal health using a …

This study tests whether in-person acupuncture or virtual acupressure can prevent joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It focuses on Non-Hispanic Black women with early-stage breast cancer, who are more likely to stop treatment du…

This study tests if eating only during an 8-hour window each day (16-hour fast) helps menopausal women lose weight and reduce menopause symptoms. It includes women going through natural menopause or those with hormone-sensitive breast cancer. 84 participants will be randomly assi…

This phase 2 trial tests whether a dexamethasone mouthwash can lower the chance of painful mouth sores (stomatitis) caused by the cancer drug datopotamab deruxtecan. About 60 people with advanced breast or lung cancer will use the mouthwash for the first five days of each treatme…

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate t…

Researchers are studying whether blood and tissue samples can show when metastatic breast cancer stops responding to standard first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The study enrolls women with ER-positive, HER2-negative metastatic breast cancer …

This study looks at whether starting with a lower dose of CDK4/6 inhibitor pills (palbociclib or ribociclib) and gradually increasing the dose helps older adults (age 65+) with metastatic breast cancer tolerate side effects better and stay on treatment longer. About 500 participa…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study looks back at the records of 800 premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who took the Oncotype DX test between 2013 and 2022. Researchers will compare how different adjuvant treatments affect 5-year invasive disease-free surv…

This study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …

This study is looking at how hormone treatments for breast cancer, called aromatase inhibitors and tamoxifen, affect blood sugar control and diabetes risk in postmenopausal women. Researchers will compare blood sugar measures in women taking these drugs to healthy women not on tr…

This study looks at whether a blood test can find tiny bits of tumor DNA left after breast cancer surgery. It includes 100 women with early-stage breast cancer that spread to 1-3 lymph nodes. The goal is to see if this test can help predict which patients are more likely to have …

This study is testing a new approach called Functional Precision Oncology for people with triple-negative or HR-low/HER2- breast cancer at high risk of early recurrence. Researchers will create personalized tumor models (in mice and lab dishes) from each patient's cancer to find …

This study is testing a new web and mobile app called SHIELD, designed to support women with hormone receptor-positive breast cancer who are on long-term hormone therapy. The goal is to see if the app is easy to use and helpful for managing treatment. About 30 women will particip…

This study is a large registry that will follow about 2,000 adults in China with a type of advanced breast cancer called HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null). The goal is to describe the patients' characteristics, genetic testing, treatment patterns, and o…

This pilot study is testing whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. Fifty participants will be randomly assigned to take their medication either within an hour of waking or within an hour …

This study is observing 3,000 people with early-stage HR+/HER2- breast cancer who are taking ribociclib or abemaciclib as part of their routine care. Researchers will look at how long patients stay cancer-free, how well they stick to their medication, and their quality of life. T…

This study tests whether a blood test called DiviTum TKa can help doctors decide to order fewer scans and other tests for women with HR+ HER2- metastatic breast cancer. The trial will enroll 55 women starting a common first-line treatment. Doctors will fill out care plans before …

This study aims to understand how the immune system reacts to a common breast cancer treatment combination of letrozole and abemaciclib. Researchers will collect tumor and blood samples from 60 postmenopausal women with hormone receptor-positive breast cancer before and after two…

This observational study will analyze tumor tissue from 100 people with BRCA1 or BRCA2 mutations and HR-positive, HER2-negative breast cancer. Researchers want to see if different molecular subtypes are linked to how well patients respond to hormone therapy or CDK4/6 inhibitors. …

This study looks at how breast cancer cells change after a short course of hormone therapy in women with and without a BRCA2 gene mutation. Researchers will measure a protein called Ki67, which indicates how fast cancer cells are growing. The goal is to see if BRCA2 carriers have…

This study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …

This study observes 750 people with a common type of breast cancer who have already been treated with surgery and are now taking CDK4/6 inhibitors to lower the risk of cancer coming back. Researchers will track how many patients experience a relapse and how well they do over time…

This study looks at whether women aged 70 and older with low-risk breast cancer can safely skip hormone therapy after surgery. Current guidelines recommend at least 5 years of hormone therapy, but older patients may face more side effects with less benefit. The trial will compare…

This observational study tracks 200 women with high-risk HR+/HER2- early breast cancer to see how many continue taking abemaciclib six months after starting. Researchers will review therapy data from 2023 to 2025. The goal is to understand real-world persistence, not to test a ne…

This study explores whether using alternative and complementary therapies, like turmeric supplements, affects how well early-stage breast cancer patients stick to their tamoxifen treatment. Researchers will follow 200 patients for one day to measure medication adherence and tamox…

This study tests whether a special type of PET scan (FFNP-PET/CT) can predict how well a drug combination (abemaciclib plus hormone therapy) works in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants with metastatic or locally adva…

This study is testing whether using simple blood tests to decide when to do scans is as effective as the usual approach of regular scans for people with advanced breast cancer. About 739 participants will be randomly assigned to either blood test monitoring or standard care. The …

This study looks at how patients with HR+/HER2- advanced or metastatic breast cancer are actually treated in China, and how well those treatments work. Researchers will analyze data from 14,000 patients to see which first-line therapies are used, how often patients switch treatme…

This study explores whether the natural bacteria in your gut affect diarrhea caused by the breast cancer drug abemaciclib. Researchers will compare stool samples from 60 women who get diarrhea with those who don't. No new treatments are given—just observation to learn why some pe…

This study is looking at a genomic test called EndoPredict that analyzes tumor genes to predict the risk of breast cancer returning. The goal is to see if women with a low-risk score can safely skip chemotherapy and only take hormone therapy. Researchers will follow 1,000 patient…

This study will follow 319 women with early-stage, hormone-sensitive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires a…

This real-world study follows 245 people with HR+/HER2- advanced breast cancer who are taking CDK4/6 inhibitors combined with hormone therapy. Researchers want to see how long the treatment controls the cancer and what options work best after the cancer becomes resistant. The goa…

This study looks at how the menstrual cycle and preoperative hormone therapy affect a marker called Ki67 in women with early hormone-positive breast cancer. Researchers will also see if adding a genetic test (PAM50) changes treatment recommendations. About 504 women will particip…

This pilot study looks at how hormone receptor positive/HER2 negative breast cancer uses glucose and other nutrients for energy. Sixteen participants with early-stage breast cancer will receive a special labeled sugar infusion before surgery. Researchers will then analyze tumor a…

This study looks at how blood components differ between younger and older women with a common type of breast cancer (HR+HER2-). Researchers will collect blood and tumor samples before and during treatment to find age-related markers that might predict how well the therapy works. …

This study looks at how sleep changes in women with early-stage breast cancer during treatment. Researchers will track sleep patterns and check for links to stress, social support, and living environment. About 100 participants will wear a sleep monitor and answer surveys before,…

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…

This study follows 700 adults with advanced or metastatic breast cancer who are taking CDK4/6 inhibitors (ciclib drugs). Researchers collect blood, tissue, and fluid samples to understand how the cancer responds, why resistance develops, and how well patients do over time. The go…

This study looks at why some hormone-receptor-positive breast cancers stop responding to hormone therapy. About 100 women with early-stage breast cancer will receive standard hormone treatment for 4-12 weeks before surgery. Researchers will analyze tumor samples to find changes i…

This observational study follows 100 people with high-risk, hormone receptor-positive, HER2-negative early breast cancer who are already taking a combination of abemaciclib, olaparib, and endocrine therapy. Researchers will track which treatments doctors choose and how patients' …